Arcturus Therapeutics (ARCT) to Release Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) will announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The company had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. During the same period in the prior year, the business posted ($1.98) EPS. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $18.35 on Wednesday. The firm has a 50-day moving average of $20.74 and a 200-day moving average of $24.39. Arcturus Therapeutics has a one year low of $17.26 and a one year high of $45.00. The company has a market cap of $494.17 million, a price-to-earnings ratio of -7.14 and a beta of 2.64.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now directly owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 15.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on ARCT shares. HC Wainwright restated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partners began coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $71.40.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.